Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02219789
Title Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements No
Sponsors Mayo Clinic
Indications

estrogen-receptor positive breast cancer

Therapies

Fulvestrant

Alisertib

Age Groups: adult
Covered Countries USA


No variant requirements are available.